The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA grants priority review for Lilly’s Verzenio (abemaciclib) for advanced breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Eli Lilly and Co. said FDA has granted Priority Review designation for its New Drug Application for Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account